202 related articles for article (PubMed ID: 29442148)
1. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
2. No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.
Li M; Hu Y; Li H; Wen Z; Hu X; Zhang D; Zhang Y; Xiao J; Tang J; Chen X
Biol Pharm Bull; 2017; 40(1):88-96. PubMed ID: 28049954
[TBL] [Abstract][Full Text] [Related]
3. Effect of
Liu S; Shi X; Tian X; Zhang X; Sun Z; Miao L
Front Pharmacol; 2017; 8():176. PubMed ID: 28408884
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
Teng R; Mitchell P; Butler K
Eur J Clin Pharmacol; 2013 Apr; 69(4):877-83. PubMed ID: 23093043
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Li H; Guo J; Carlson GF; Teng R
Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
Jeon HS; Kim MJ; Choi HY; Kim YH; Kim EH; Kim AR; Park HJ; Bae KS; Lim HS
Clin Ther; 2015 Mar; 37(3):563-73. PubMed ID: 25697420
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
[TBL] [Abstract][Full Text] [Related]
8. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
Röshammar D; Bergstrand M; Andersson T; Storey RF; Hamrén B
Int J Clin Pharmacol Ther; 2017 May; 55(5):416-424. PubMed ID: 28139972
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
Li H; Butler K; Yang L; Yang Z; Teng R
Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.
Amilon C; Niazi M; Berggren A; Åstrand M; Hamrén B
Clin Pharmacokinet; 2019 Oct; 58(10):1295-1307. PubMed ID: 30972696
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.
Teng R; Butler K
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):478-91. PubMed ID: 24755129
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
Teng R; Butler K
Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
[TBL] [Abstract][Full Text] [Related]
18. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
Trials; 2015 Apr; 16():198. PubMed ID: 25925591
[TBL] [Abstract][Full Text] [Related]
19. Effects of food and gender on pharmacokinetics of ticagrelor and its main active metabolite AR-C124910XX in healthy Chinese subjects
.
Feng W; Liu D; Wang Y; Shi X; Liu F; Sun L; Ding L
Int J Clin Pharmacol Ther; 2018 Aug; 56(8):372-380. PubMed ID: 29932414
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Butler K; Teng R
Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
